ATE374194T1 - Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5 - Google Patents
Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5Info
- Publication number
- ATE374194T1 ATE374194T1 AT02805227T AT02805227T ATE374194T1 AT E374194 T1 ATE374194 T1 AT E374194T1 AT 02805227 T AT02805227 T AT 02805227T AT 02805227 T AT02805227 T AT 02805227T AT E374194 T1 ATE374194 T1 AT E374194T1
- Authority
- AT
- Austria
- Prior art keywords
- heteroaryl
- modulators
- metabotropic
- glutamatareceptor
- treatment
- Prior art date
Links
- 150000003852 triazoles Chemical class 0.000 title 1
- 102000012777 Metabotropic Glutamate 5 Receptor Human genes 0.000 abstract 2
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 208000011117 substance-related disease Diseases 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000017164 Chronobiology disease Diseases 0.000 abstract 1
- 206010013654 Drug abuse Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 abstract 1
- -1 Triazole compounds Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34158201P | 2001-12-18 | 2001-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE374194T1 true ATE374194T1 (de) | 2007-10-15 |
Family
ID=23338164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02805227T ATE374194T1 (de) | 2001-12-18 | 2002-12-13 | Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7105548B2 (de) |
| EP (1) | EP1458708B1 (de) |
| JP (1) | JP4299139B2 (de) |
| AT (1) | ATE374194T1 (de) |
| AU (1) | AU2002366388B2 (de) |
| CA (1) | CA2469821C (de) |
| DE (1) | DE60222698T2 (de) |
| ES (1) | ES2292854T3 (de) |
| WO (1) | WO2003051315A2 (de) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60223720T2 (de) * | 2001-12-18 | 2008-10-30 | Merck & Co., Inc. | Heteroaryl-substituierte pyrazol-modulatoren des metabotropen glutamatrezeptors-5 |
| EP1485093B1 (de) * | 2002-03-12 | 2010-11-03 | Merck Sharp & Dohme Corp. | Di-aryl-substituierte tetrazol-modulatoren des metabotropen glutamat-rezeptors-5 |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| CA2520863A1 (en) * | 2003-04-03 | 2004-10-14 | Merck & Co., Inc. | 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5 |
| CN100387594C (zh) * | 2003-04-03 | 2008-05-14 | 麦克公司 | 二芳基取代的吡唑类代谢型谷氨酸受体-5调节剂 |
| EP1613617A4 (de) | 2003-04-04 | 2009-02-18 | Merck & Co Inc | Diarylsubstituierte triazolmodulatoren des metabotropen glutamatrezeptors-5 |
| JP2007504229A (ja) * | 2003-09-02 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類 |
| CA2555402A1 (en) * | 2004-02-12 | 2005-09-01 | Celine Bonnefous | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 |
| CN1934094A (zh) * | 2004-03-05 | 2007-03-21 | 万有制药株式会社 | 二芳基取代杂环5元环衍生物 |
| EP1734963A4 (de) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | Verfahren zur behandlung von menschen mit metabolischen und anthropometrischen störungen |
| DE102004044884A1 (de) | 2004-09-14 | 2006-05-24 | Grünenthal GmbH | Substituierte bizyklische Imidazo-3-yl-amin-Verbindungen |
| EP2402323A3 (de) | 2004-10-13 | 2012-05-30 | PTC Therapeutics, Inc. | Pyrazol- oder Triazolverbindungen und ihre Verwendung zur Herstellung eines Heilmittels zur Behandlung durch somatische Mutationen bewirkter Krankheiten |
| WO2007007909A1 (ja) * | 2005-07-13 | 2007-01-18 | Banyu Pharmaceutical Co., Ltd. | ジアリール置換複素５員環誘導体を含む併用薬 |
| EP2275095A3 (de) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenese durch modulation des Muscarinrezeptors |
| EP2258358A3 (de) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenese mit Acetylcholinesterasehemmer |
| EP1940389A2 (de) | 2005-10-21 | 2008-07-09 | Braincells, Inc. | Modulation von neurogenese durch pde-hemmung |
| AU2006308889A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | GABA receptor mediated modulation of neurogenesis |
| US7951824B2 (en) | 2006-02-17 | 2011-05-31 | Hoffman-La Roche Inc. | 4-aryl-pyridine-2-carboxyamide derivatives |
| US20070244143A1 (en) * | 2006-03-08 | 2007-10-18 | Braincells, Inc | Modulation of neurogenesis by nootropic agents |
| US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| JP2009536667A (ja) * | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | ５ｈｔ受容体介在性の神経新生 |
| EP2382975A3 (de) | 2006-05-09 | 2012-02-29 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
| US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| AU2007292848A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| AU2007299920A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | PPAR Mediated Modulation of Neurogenesis |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2009019278A1 (en) * | 2007-08-08 | 2009-02-12 | Neurosearch A/S | Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
| JPWO2009028543A1 (ja) * | 2007-08-30 | 2010-12-02 | 武田薬品工業株式会社 | 置換ピラゾール誘導体 |
| DE102007044032A1 (de) | 2007-09-14 | 2009-03-19 | Bayer Healthcare Ag | Substituierte heterocyclische Verbindungen und ihre Verwendung |
| AU2008309621A1 (en) * | 2007-10-12 | 2009-04-16 | Novartis Ag | Metabotropic glutamate receptor modulators for the treatment of Parkinson's Disease |
| DE102007049157A1 (de) | 2007-10-13 | 2009-04-16 | Bayer Healthcare Ag | Substituierte Dihydrotriazolone und ihre Verwendung |
| WO2009112459A1 (en) * | 2008-03-11 | 2009-09-17 | Neurosearch A/S | Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
| ES2522968T3 (es) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| JP2011530495A (ja) * | 2008-08-08 | 2011-12-22 | ノイロサーチ アクティーゼルスカブ | ニコチン性アセチルコリン受容体のモジュレーターとして有用な新規のジフェニル１，２，３−トリアゾール誘導体 |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US8772301B2 (en) | 2009-12-18 | 2014-07-08 | Sunovion Pharmaceuticals, Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| AR087119A1 (es) * | 2011-07-12 | 2014-02-12 | Dow Agrosciences Llc | Composiciones plaguicidas y procesos relacionados |
| EP2822931B1 (de) | 2012-03-09 | 2017-05-03 | Inception 2, Inc. | Triazolonverbindungen und verwendungen davon |
| SG11201504622PA (en) | 2012-12-20 | 2015-07-30 | Inception 2 Inc | Triazolone compounds and uses thereof |
| US20140275564A1 (en) * | 2013-03-13 | 2014-09-18 | Dow Agrosciences Llc | Process for the preparation of certain triaryl rhamnose carbamates |
| AU2014235215A1 (en) | 2013-03-15 | 2015-10-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
| BR112015030326A2 (pt) | 2013-06-05 | 2017-08-29 | Synergy Pharmaceuticals Inc | Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos |
| GB201312800D0 (en) * | 2013-07-17 | 2013-08-28 | Heptares Therapeutics Ltd | mGlu5 modulators |
| CN105579440A (zh) | 2013-09-06 | 2016-05-11 | 因森普深2公司 | 三唑酮化合物及其应用 |
| BR112016011753A2 (pt) | 2013-12-13 | 2020-11-03 | Halliburton Energy Services, Inc | Método para realização de medições de ressonância magnética de uma amostra e sistema para a realização de medições de ressonância magnética de uma amostra |
| CN106414429B (zh) | 2014-06-03 | 2020-01-03 | 爱杜西亚药品有限公司 | 吡唑化合物及其作为t型钙通道阻断剂的用途 |
| US10246426B2 (en) | 2014-09-15 | 2019-04-02 | Idorsia Pharmaceuticals Ltd | Triazole compounds as T-type calcium channel blockers |
| WO2016202935A1 (en) | 2015-06-19 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Glucose transport inhibitors |
| MX388586B (es) | 2016-12-16 | 2025-03-20 | Idorsia Pharmaceuticals Ltd | Combinacion farmaceutica que comprende un bloqueador del canal de calcio de tipo t. |
| CA3050348A1 (en) | 2017-02-06 | 2018-08-09 | Idorsia Pharmaceuticals Ltd | A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes |
| PL3634417T3 (pl) | 2017-05-17 | 2023-09-25 | Arcus Biosciences, Inc. | Pochodne chinazolino-pirazolowe do leczenia chorób związanych z nowotworem |
| US12378229B2 (en) | 2021-02-02 | 2025-08-05 | Liminal Biosciences Limited | GPR84 antagonists and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| OA09122A (en) * | 1988-07-08 | 1991-10-31 | Schering Agrochemicals Ltd | Triazole insecticides. |
| JP3217846B2 (ja) * | 1992-03-04 | 2001-10-15 | クミアイ化学工業株式会社 | トリアゾール誘導体及び殺虫剤 |
| KR100875222B1 (ko) * | 1999-08-19 | 2008-12-19 | 아스트라제네카 아베 | 헤테로폴리사이클릭 화합물 및 간접 글루타메이트 수용체길항제로서의 그들의 용도 |
| BR0209499A (pt) * | 2001-05-09 | 2004-07-06 | Sumitomo Chem Takeda Agro Co | Composto, processo para produzir o composto, e, composição pesticida |
-
2002
- 2002-12-13 DE DE60222698T patent/DE60222698T2/de not_active Expired - Fee Related
- 2002-12-13 US US10/499,391 patent/US7105548B2/en not_active Expired - Fee Related
- 2002-12-13 AT AT02805227T patent/ATE374194T1/de not_active IP Right Cessation
- 2002-12-13 EP EP02805227A patent/EP1458708B1/de not_active Expired - Lifetime
- 2002-12-13 JP JP2003552248A patent/JP4299139B2/ja not_active Expired - Fee Related
- 2002-12-13 AU AU2002366388A patent/AU2002366388B2/en not_active Ceased
- 2002-12-13 ES ES02805227T patent/ES2292854T3/es not_active Expired - Lifetime
- 2002-12-13 CA CA002469821A patent/CA2469821C/en not_active Expired - Fee Related
- 2002-12-13 WO PCT/US2002/041720 patent/WO2003051315A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1458708A4 (de) | 2005-11-16 |
| DE60222698T2 (de) | 2008-06-19 |
| AU2002366388A1 (en) | 2003-06-30 |
| US20050020585A1 (en) | 2005-01-27 |
| DE60222698D1 (de) | 2007-11-08 |
| EP1458708A2 (de) | 2004-09-22 |
| CA2469821C (en) | 2009-10-20 |
| CA2469821A1 (en) | 2003-06-26 |
| WO2003051315A2 (en) | 2003-06-26 |
| AU2002366388B2 (en) | 2008-09-18 |
| US7105548B2 (en) | 2006-09-12 |
| EP1458708B1 (de) | 2007-09-26 |
| JP2005516920A (ja) | 2005-06-09 |
| JP4299139B2 (ja) | 2009-07-22 |
| WO2003051315A3 (en) | 2003-10-23 |
| ES2292854T3 (es) | 2008-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE374194T1 (de) | Heteroarylsubstituierte triazolmodulatoren des metabotropen glutamatarezeptors 5 | |
| ATE486600T1 (de) | Di-aryl-substituierte tetrazol-modulatoren des metabotropen glutamat-rezeptors-5 | |
| CA2469813A1 (en) | Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | |
| WO2003053922A3 (en) | Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 | |
| WO2004089303A3 (en) | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 | |
| WO2005079802A8 (en) | Bipyridyl amides as modulators of metabotropic glutamate receptor-5 | |
| WO2004089306A3 (en) | Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5 | |
| EP1434773A4 (de) | Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5 | |
| WO2004089308A3 (en) | Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5 | |
| DK0975595T3 (da) | Kokainanaloger | |
| MXPA04005444A (es) | Ureas de 2-aminobenzotiazoles como moduladores de adenosina. | |
| DE60124085D1 (de) | Pde-v hemmer zur behandlung von morbus parkinson | |
| HUP0202636A2 (hu) | Alkilén-diamin-csoporttal helyettesített heterogyűrűs vegyületek és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| DK1632483T3 (da) | Heterocykliske, substituerede carbonylderivater og deres anvendelse som dopamin-D3-receptorligander | |
| EA200601269A1 (ru) | Лекарственное средство, содержащее производные фенилпиперазина | |
| WO2004087653A3 (en) | 4-ring imidazole derivatives as modulators of metabotropic glutamate receptor-5 | |
| UA83691C2 (ru) | Применение замещенных 2-аминотетралинов для упреждающего лечения болезни паркинсона | |
| TW200502221A (en) | Novel lactams and uses thereof | |
| DE50114170D1 (de) | Dopamin-d3-rezeptor-liganden zur behandlung von sucht | |
| ATE398614T1 (de) | Triazolverbindungen und ihre therapeutische verwendung | |
| DE69925160D1 (de) | Arylpiperidin- und aryl-1,2,5,6-tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität | |
| TW200510331A (en) | Heteroaryl-substituted imidazole derivatives | |
| DE60224509D1 (de) | Imidazolderivate verwendbar als histamin h3 rezeptorliganden | |
| ATE418973T1 (de) | Spirocyclopropyl-amide und -säuren und ihre therapeutischen anwendungen | |
| DE60200531D1 (de) | Mikroemulsionen zur transdermalen Verabreichung von Apomorphin für die Behandlung von Morbus Parkinson |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |